Bimekizumab hit PASI 90 in 85% of patients versus 50% for ustekinumab, resetting psoriasis's efficacy bar across six competing mechanisms.

The moderate-to-severe plaque psoriasis market is no longer contested on PASI 75. Bimekizumab (Bimzelx), which blocks both IL-17A and IL-17F, delivered PASI 90 in 85% of patients at week 16 in BE VIVID versus 50% for ustekinumab. IL-23p19 agents guselkumab (Tremfya, VOYAGE 1: PASI 90 73.3% vs adalimumab 49.7%) and risankizumab (Skyrizi, UltIMMa: PASI 90 75.3% vs ustekinumab 42%) pair that clearance with quarterly (q12w) maintenance dosing, which has made risankizumab the volume leader in the class.

The older mechanisms are now the defended flank. Ustekinumab (IL-12/23) and adalimumab (TNF) both face US biosimilar erosion, and the two remaining branded battlegrounds are convenience and route: deucravacitinib (Sotyktu), the first oral selective TYK2 inhibitor, cleared PASI 75 in 58.4% at week 16 versus 35.1% for apremilast and 12.7% for placebo in POETYK PSO-1, positioning it as the oral that finally beats apremilast rather than another injectable.

Once PASI 90 is table stakes, dosing interval decides who wins share.

Five questions this report answers:

Q1 - Does incremental clearance beyond PASI 90 still move share, or has dosing interval taken over?

Q2 - Can oral deucravacitinib expand the biologic-eligible pool, or does it mainly replace apremilast?

Q3 - Where does branded defense hold as ustekinumab and adalimumab biosimilars enter the US market?

Q4 - What do BE VIVID's 85% and UltIMMa's 75.3% PASI 90 rates mean for prescriber choice?

Q5 - How did deucravacitinib's 58.4% PASI 75 rate compare with apremilast's 35.1% in POETYK PSO-1?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Psoriasis #US #CompetitiveIntelligence #AXLRx #Dermatology #PharmaMarketAccess

Live report page:  https://axlrx.ai/psoriasis/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/